|
|
 |
|
Viewing report
|
|
|
|
Poland Pharmaceuticals and Healthcare Report Q1 2010
Business Monitor International, Nov 2009, Pages: 82
Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry.
Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry.
Poland is one of the highest value markets in Central and Eastern Europe (CEE) and as a result is a destination for almost all multinationals operating within the region. Poland’s pharmaceutical market has shown consistently strong growth during 2009, despite economic pressures. Over the next 10 years the authors forecast that pharmaceutical sales will record a compound annual growth rate (CAGR) of 7.9% in US dollar terms, highlighting its potential for foreign investors.
Poland, however, does have a number of drawbacks which make it less than perfect, particularly for Big Pharma. In Q110 Business Environment Ratings, Poland places sixth out of the 20 CEE markets in our coverage universe. While scoring relatively well in both pharmaceutical market and country risk categories, demographic and market risk factors constrain a table-topping score. One of the major frustrations for multinationals is delays in reimbursement for innovative products and a strong preference for the domestic industry.
Budgeted spending on healthcare by the National Health Fund (NFZ) has increased rapidly from PLN33.1bn (US$10.2bn) in 2005 to PLN56.2bn (US$16.7bn) in 2009, a CAGR of 14.1%. While increases for 2009 alone were lower at just 4.4%, the figures can still be viewed as positive for the healthcare industry. Increases were seen across the majority of sub-sectors, including reimbursement of pharmaceuticals.
NFZ President Jacek Paszkiewicz believes that the fund’s budget for 2010 will have to be reduced by PLN2bn (US$686mn), which represents a 3.6% contraction on current 2009 budget figures. Furthermore, fund income in 2011 is set to drop further with reserves again required to support spending. Paszkiewicz expects strikes within the healthcare sector as a result of a future inability to support wage demands. Regulatory updates mean a large number of food supplements, including vitamins and minerals, slimming preparations and dermatological products are likely to be withdrawn from sale in Poland from January 1 2010. Products which are currently available for sale without being registered as medicines will be forced to obtain licences.
Company-wise, biotechnology firm Bioton build strong international operations focused on insulin sales, biotechnological product development and strategic alliances. In late 2009 it was rumoured the firm would extend it’s collaboration with Bayer-Schering to distribute recombinant insulin product SciLin in Russia, following a similar deal in China earlier in the year.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Poland Pharmaceuticals and Healthcare Report Q1 2011
Poland Pharmaceuticals and Healthcare Report Q3 2011
Poland Pharmaceuticals and Healthcare Report Q2 2012
Poland Pharmaceuticals and Healthcare Report Q4 2010
Poland Pharmaceuticals and Healthcare Report Q3 2010
Poland Pharmaceuticals and Healthcare Report Q2 2010
Poland Pharmaceuticals and Healthcare Report Q1 2009
Opportunities in Emerging Markets - Central and Eastern Europe, Russia, and Ukraine
Poland Pharmaceuticals and Healthcare Report Q4 2008
Poland Pharmaceuticals and Healthcare Report Q2 2008
|
|
|
|
